Posaconazole

Nature Reviews Drug Discovery

Volumn 6, Issue 3, 2007, Pages 183-184

  Kauffman, Carol A ^a   Malani, Anurag N ^a   Easley, Chris ^b   Kirkpatrick, Peter ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DRUG APPROVAL; DRUG ERUPTION; DRUG INDICATION; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; PHOTOSENSITIVITY; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CAPSULES; DRUG APPROVAL; DRUG DESIGN; ECONOMICS, PHARMACEUTICAL; FLUCONAZOLE; HUMANS; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS; SUSPENSIONS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT FAILURE; TRIAZOLES; UNITED STATES;

EID: 33847396517     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2270     Document Type: Article

References (15)

1. Kauffman, C. A. Clinical efficacy of new antifungal agents. Curr. Opin. Microbiol. 9, 483-488 (2006).
2. Torres, H. A. et al. Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect. Dis. 5, 775-785 (2005).
3. Odds, F. C. et al. Antifungal agents: Mechanisms of action. Trends Microbiol. 11, 272-279 (2003).
4. Bennett, F. et al. Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. Bioorg. Med. Chem. Lett. 16, 86-90 (2006).
5. Ullmann, A. J. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335-347 (2007).
6. Cornely, O. A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348-359 (2007).
7. FDA labelling information [online], (2006).
8. Kauffman, C. A. Zygomycosis: Reemergence of an old pathogen. Clin. Infect. Dis. 39, 588-590 (2004).
9. Greenberg, R. N. et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50, 126-133 (2006).
10. Van Burik, J. H. et al. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin. Infect. Dis. 42, e61-e65 (2006).
11. Walsh, T. J. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin. Infect. Dis. 44, 2-12 (2007).
12. Raad, I. I. et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42, 1398-1403 (2006).
13. Anstead, G. M. et al. Refractory coccidioidomycosis treated with posaconazole. Clin. Infect. Dis. 40, 1770-1776 (2005).
14. Johnson, L. B. & Kauffman, C. A. Voriconazole: A new triazole antifungal agent. Clin. Infect. Dis. 36, 630-637 (2003).
15. Sansone-Parsons, A. et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50, 1881-1883 (2006).